SE8406511L - Farmaceutisk komposition med tumorhemmande effekt - Google Patents

Farmaceutisk komposition med tumorhemmande effekt

Info

Publication number
SE8406511L
SE8406511L SE8406511A SE8406511A SE8406511L SE 8406511 L SE8406511 L SE 8406511L SE 8406511 A SE8406511 A SE 8406511A SE 8406511 A SE8406511 A SE 8406511A SE 8406511 L SE8406511 L SE 8406511L
Authority
SE
Sweden
Prior art keywords
pref
cooh
antitumour
antibody
pharmaceutical composition
Prior art date
Application number
SE8406511A
Other languages
English (en)
Other versions
SE8406511D0 (sv
Inventor
C Yoshikumi
T Fujii
M Fujii
K Matsunaga
Y Oguchi
K Niimura
Original Assignee
Kureha Chemical Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP16138878A external-priority patent/JPS5592325A/ja
Priority claimed from JP14215379A external-priority patent/JPS5665829A/ja
Priority claimed from JP14215279A external-priority patent/JPS5665828A/ja
Application filed by Kureha Chemical Ind Co Ltd filed Critical Kureha Chemical Ind Co Ltd
Publication of SE8406511L publication Critical patent/SE8406511L/sv
Publication of SE8406511D0 publication Critical patent/SE8406511D0/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE8406511A 1978-12-29 1984-12-20 Farmaceutisk komposition med tumorhemmande effekt SE8406511D0 (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP16138878A JPS5592325A (en) 1978-12-29 1978-12-29 Antitumor agent and its preparation
JP14215379A JPS5665829A (en) 1979-11-02 1979-11-02 Antitumor agent
JP14215279A JPS5665828A (en) 1979-11-02 1979-11-02 Antitumor agent

Publications (2)

Publication Number Publication Date
SE8406511L true SE8406511L (sv) 1984-12-20
SE8406511D0 SE8406511D0 (sv) 1984-12-20

Family

ID=27318393

Family Applications (3)

Application Number Title Priority Date Filing Date
SE7910483A SE7910483L (sv) 1978-12-29 1979-12-19 Farmaceutisk komposition med tumorhemmande effekt
SE8406510A SE8406510D0 (sv) 1978-12-29 1984-12-20 Farmaceutisk komposition med tumorhemmande effekt
SE8406511A SE8406511D0 (sv) 1978-12-29 1984-12-20 Farmaceutisk komposition med tumorhemmande effekt

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SE7910483A SE7910483L (sv) 1978-12-29 1979-12-19 Farmaceutisk komposition med tumorhemmande effekt
SE8406510A SE8406510D0 (sv) 1978-12-29 1984-12-20 Farmaceutisk komposition med tumorhemmande effekt

Country Status (8)

Country Link
US (2) US4315851A (sv)
CH (1) CH655010A5 (sv)
DE (1) DE2952690C2 (sv)
FR (1) FR2445149B1 (sv)
GB (1) GB2038836B (sv)
IT (1) IT1127324B (sv)
PH (1) PH16902A (sv)
SE (3) SE7910483L (sv)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4501692A (en) * 1979-07-26 1985-02-26 Syva Company Charge effects in enzyme immunoassays
JPS57106626A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
JPS57106625A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
JPS58116496A (ja) * 1981-12-29 1983-07-11 Nippon Kayaku Co Ltd アミドｎ置換ブレオマイシン類
JPS59116232A (ja) * 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体及びその製造法
JPH0651643B2 (ja) * 1983-01-19 1994-07-06 帝人株式会社 殺細胞性修飾免疫グロブリン及びその製造方法
GR79899B (sv) * 1983-03-30 1984-10-31 Lilly Industries Ltd
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
GB2142428A (en) * 1983-06-23 1985-01-16 Erba Farmitalia Adenocarcinoma related antigenic determinants and antibodies specific thereto
GB8317022D0 (en) * 1983-06-23 1983-07-27 Erba Farmitalia Adenocarcinoma related new antigenic determinants
FR2584293B1 (fr) * 1985-07-04 1989-03-17 Ire Celltarg Sa Anticorps utiles comme agents de pilotage et conjugues les incorporant
JPS63502112A (ja) * 1986-01-03 1988-08-18 コンソリデイテツド・フアーマシユーテイカルズ・リミテツド メルファラン誘導体
GB8601406D0 (en) * 1986-01-21 1986-02-26 Ucb Bioproducts Conjugate of x-melanotropine with p-l-sarcolysine
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5004606A (en) * 1986-09-24 1991-04-02 Hybritech Incorporated Non-covalent antibody-anthracycline immunocomplexes
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
DE4122210C2 (de) * 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung
ATE127018T1 (de) * 1992-03-06 1995-09-15 Fiutowski Zdzislaw Pharmazeutische zusammensetzung mit antiviraler und antibakterieller wirkung.
JP2578044B2 (ja) * 1992-03-14 1997-02-05 呉羽化学工業株式会社 フェニルアラニン−グリシン誘導体、その製造方法、及びその誘導体を含有する抗腫瘍剤
US5382582A (en) * 1993-03-26 1995-01-17 Chan; Carcy L. Methotrexate analogs and methods of using same
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
US6372217B1 (en) * 1997-06-03 2002-04-16 Regents Of The University Of Minnesota Methods for the treatment of CD7+ viral infection with TXU-7-PAP
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US7306919B1 (en) 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
KR100978705B1 (ko) * 2002-03-18 2010-08-30 다이닛본 스미토모 세이야꾸 가부시끼가이샤 폐암 치료
ES2425083T3 (es) * 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
EP3075247B1 (en) * 2004-02-02 2022-10-12 BioSight Ltd. Conjugates for cancer therapy and diagnosis
US7612071B2 (en) * 2004-03-12 2009-11-03 Syntrix Biosystems, Inc. Compositions and methods employing aminopterin
WO2006031614A2 (en) * 2004-09-10 2006-03-23 Tosk, Inc. Reduced toxicity methotrexate formulations and methods for using the same
SG170037A1 (en) 2005-11-28 2011-04-29 Verrow Pharmaceuticals Inc Compositions useful for reducing nephrotoxicity and methods of use thereof
EP2265274B1 (en) 2008-03-03 2018-11-21 Tosk, Inc. Methotrexate adjuvants to reduce toxicity and methods for using the same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT300193B (de) 1969-01-17 1972-07-10 Agricura Labor Ltd Verfahren zur Herstellung von Mastitis-Immunoglobulin
IL34079A (en) * 1969-04-01 1973-02-28 Upjohn Co Purification of ypsilon-globulins
US3917818A (en) * 1970-01-14 1975-11-04 Agricura Labor Ltd Treatment of mastitis in cows, the product for this treatment and to the production of said product
SE348942B (sv) * 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US3983001A (en) * 1972-05-10 1976-09-28 Ceskoslovenska Akademie Ved Isolation of biologically active compounds by affinity chromatography
US4160019A (en) * 1973-06-25 1979-07-03 Bjorklund Knut B Detection of cancer associated polypeptide antigen and preparation of antibodies thereto
US3947352A (en) * 1974-05-31 1976-03-30 Pedro Cuatrecasas Polysaccharide matrices for use as adsorbents in affinity chromatography techniques
GB1509707A (en) 1974-09-20 1978-05-04 Searle & Co Immunological compounds
GB1541435A (en) 1975-02-04 1979-02-28 Searle & Co Immunological materials
US4195017A (en) * 1975-02-25 1980-03-25 Samuel Bogoch Malignin, derived from brain tumor cells, complexes and polypeptides thereof
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
US4263279A (en) * 1975-08-19 1981-04-21 Yeda Research & Development Co. Ltd Pharmaceutically active compositions containing adriamycin and daunomycin
US4152410A (en) * 1975-09-03 1979-05-01 Eisai Co., Ltd. Diagnosis reagent for neoplasm and method for diagnosis of neoplasm
US4017471A (en) * 1975-09-15 1977-04-12 G. D. Searle & Co. Immunological compounds
GB1541436A (en) 1976-02-02 1979-02-28 Searle & Co Immunological materials
US4123427A (en) * 1976-07-27 1978-10-31 Daniel Thomas M Method for the purification of mycobacterial protein antigens and resulting product
DE2862449D1 (en) * 1977-08-22 1984-11-22 Nat Res Dev Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them
US4228237A (en) * 1978-09-21 1980-10-14 Calbiochem-Behring Corp. Methods for the detection and determination of ligands
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4223005A (en) * 1979-02-15 1980-09-16 University Of Illinois Foundation Antibody coated bacteria

Also Published As

Publication number Publication date
IT7928464A0 (it) 1979-12-31
DE2952690C2 (de) 1984-11-08
GB2038836B (en) 1982-11-24
IT1127324B (it) 1986-05-21
DE2952690A1 (de) 1980-07-03
US4401592A (en) 1983-08-30
FR2445149B1 (fr) 1989-12-29
SE8406510L (sv) 1984-12-20
SE8406511D0 (sv) 1984-12-20
GB2038836A (en) 1980-07-30
CH655010A5 (de) 1986-03-27
SE8406510D0 (sv) 1984-12-20
FR2445149A1 (fr) 1980-07-25
SE7910483L (sv) 1980-06-30
PH16902A (en) 1984-04-10
US4315851A (en) 1982-02-16

Similar Documents

Publication Publication Date Title
SE8406511D0 (sv) Farmaceutisk komposition med tumorhemmande effekt
IL73104A0 (en) 2-amino-5-hydroxy-4-methyl-pyrimidine derivatives
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
GR3033524T3 (en) Steroids which inhibit angiogenesis.
PL307265A1 (en) Compounds containing a phenyl group bonded with aryl or heteroaryl group through their bonding aliphatic group or that containing heteroatom
ATE192655T1 (de) Verwendung von histamin-gamma-globulin zur herstellung eines immunomodulierenden und antiinflammatorischen agens
DK0585939T4 (da) TNF-ligander
IL68456A (en) Pharmaceutical compositions comprising perfluoro-substituted compounds as vehicles
NO932517L (no) 5,10-metylentetrahydrofolsyre-syklo-dekstrin-inkulusjonsforbindels er
FR2707638B1 (fr) Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique.
FI102377B1 (sv) Förfarande för framställning av terapeutiskt användbara 4-amino- 4-steroider
KR910018038A (ko) 원발성 흉막암의 치료를 위한 제약 조성물 제조용 인체 인터루킨 2활성 함유 폴리펩티드의 용도
SV1996000001A (es) Nuevas aplicaciones de dimero de lisozima
EP0227809A4 (en) METHOD AND COMPOSITION FOR TREATING CANCER AND NON-MALIGNAL TUMORS.
ES2095938T3 (es) Procedimiento y composiciones para el tratamiento de lesiones.
ATE66819T1 (de) Antikoerper und antikoerper enthaltende zubereitungen fuer die inhibition von periodontitis.
FR2704547B1 (fr) Nouveaux composés pyrrolopyraziniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
DK0672685T3 (da) Monoklonalt antistof specifik for tumor cytotoxisk faktor (TCF-11)
FR2721612B1 (fr) Nouveaux dérivés d'oligosides, leur procédé de préparation et leurs applications.
GR3015132T3 (en) Novel ureas and thioureas, preparation thereof and application in therapy.
GR3004764T3 (sv)
ATE129638T1 (de) Pharmazeutische zusammensetzungen zur behandlung der parkinson'schen krankheit.
OA07716A (fr) Dérivés d'acides isoindoledicarboxyliques, leur préparation et compositions pharmaceutiques les contenant.
ATE40380T1 (de) Anthracykline verbindung, verfahren zu deren herstellung, deren pharmazeutische zusammensetzung und deren verwendung als arzneimittel.
JPS5665829A (en) Antitumor agent

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 8406511-9

Effective date: 19911215